Command Palette
Search for a command to run...
YAP/TAZ-controlled ERK dynamics coordinate progenitor expansion and differentiation commitment
Sharma, S.; Berger, H. A.; Zhang, Z.; Meyer, T.; Teruel, M. N.
YAP and TAZ hold PPARG below the threshold for irreversible differentiation commitment by maintaining a fluctuating high-ERK state, and MEK-ERK inhibition restores differentiation even when YAP/TAZ activity remains high.
Moderate contradiction
2 prior failuresTwo documented clinical failures match this mechanism, or a single Phase 3 failure is on record.
Abstract excerpt
Progenitor cells must proliferate to expand the cell population, yet terminal differentiation requires this proliferative state to end. How signaling controls the duration of this proliferative window remains poorly understood. Using adipogenesis and live single-cell imaging of differentiation, cell-cycle, and ERK-activity reporters, we show that YAP and TAZ coordinate progenitor expansion with differentiation commitment by regulating ERK dynamics. YAP/TAZ maintain cells in a fluctuating high-ERK state that promotes proliferation while actively keeping the differentiation driver PPARG below the threshold for irreversible commitment. Crucially, this differentiation block is not explained by proliferation alone: inhibiting CDK4/6 or AKT suppressed proliferation without restoring differentiation, whereas MEK-ERK inhibition restored differentiation even when YAP/TAZ activity remained high. As YAP/TAZ activity decreases, dampened ERK fluctuations trigger PPARG activation. These findings support a self-limiting model in which YAP/TAZ-driven progenitor expansion progressively increases cell density and contact-dependent Hippo signaling, reducing YAP/TAZ activity and terminating the proliferative phase. Consequently, transient YAP/TAZ activation expands the progenitor pool while preserving subsequent differentiation, whereas sustained activation suppresses commitment. Together, these findings identify YAP/TAZ-controlled ERK dynamics as the nexus coordinating progenitor expansion with terminal differentiation and suggest that slower density-dependent Hippo feedback may set the duration of this proliferative window to regulate differentiated cell-number output.
Matching Claidex post-mortems
2 of 2 indexed- Sep 21, 2026MBX-102 (arhalofenate): a PPARγ partial agonist that traded away the efficacy it needed in type 2 diabetesMBX-102 (arhalofenate, JNJ-39659100)EfficacyMRS 49
- Jul 30, 2026Pioglitazone for sympathetic overactivity in CKD: the biomarker the trial was built on was not therePioglitazoneBiomarkerMRS 49
This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.

